Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies

Figure 2

Non-IgG mAb structures. Recombinant technology allows the manufacture of novel mAb structures that allow altered affinity, avidity, tissue penetration, and tissue half-life. Antibody structures include fragments, orthodox (IgG-like structures), and heterodox (non-IgG-like structures). Some antibodies are developed to contain multiple binding sites, allowing improved avidity (i.e., tandem diabody), and different binding sites (i.e., (ScFv)₂/BITE which can bind to two targets). ScFv = single chain variable fragment. BITE = bi-specific T-cell engager.